Indivior's Recent FDA Announcement
RICHMOND, Va. - Indivior PLC (NASDAQ:LSE: INDV), a dedicated pharmaceutical company, has exciting news to share with the healthcare community and patients battling opioid use disorder (OUD). The U.S. Food and Drug Administration (FDA) has granted Priority Review for a Prior Approval Supplement (PAS) concerning SUBLOCADE (buprenorphine extended-release) injection. This development aims to broaden the usage of SUBLOCADE by including alternative injection sites and introducing a rapid induction protocol that could significantly meet the urgent needs of patients and healthcare providers.
Updated Administration Methods for SUBLOCADE
The proposed changes in the drug labeling allow for subcutaneous administration not just in the abdomen but also in the thigh, buttock, and the upper arm's back. Furthermore, this new protocol could potentially shorten the induction period from the traditional seven days down to just one hour, following a single dose of transmucosal buprenorphine. This expedited induction could enable the administration of a second dose as early as one week after the initial shot, catering to patient-specific needs.
Evidence Supporting the New Protocol
Indivior's submission to the FDA is backed by thorough data, showcasing the safety and effectiveness of SUBLOCADE when employed with this new rapid induction method and the proposed alternative injection sites. The Priority Review status indicates that the FDA aims to finalize its review within six months—much quicker than the usual ten-month timeline.
The Role of SUBLOCADE in Treating OUD
Currently, SUBLOCADE is indicated for treating moderate to severe opioid use disorder in patients who have begun treatment with a buprenorphine-containing product, followed by dose adjustments for at least a week. Importantly, it is not intended for use alone; comprehensive treatment programs including counseling and psychosocial support are essential for optimal outcomes.
Safety and Common Side Effects
As with any medication, SUBLOCADE comes with its risks. It carries a boxed warning regarding the serious potential risks associated with intravenous administration. Patients can only access this medication through a restricted program known as the SUBLOCADE REMS Program due to these dangers. Common side effects reported include constipation, headache, nausea, injection site itching, vomiting, increased hepatic enzymes, fatigue, and injection site pain.
Implications of FDA's Decision Timeline
The FDA's final verdict regarding the PAS is anticipated in early February. An approval for these label expansions could represent a transformative step in how OUD is treated with SUBLOCADE, potentially leading to a broader range of patients benefiting from this therapy.
Recent Developments for Indivior PLC
In addition to the recent FDA news, Indivior PLC has been navigating various developments. Craig-Hallum recently revised its stock price target for Indivior from $24.00 to $20.00 but retained a Buy rating, reflective of ongoing reassessment of the company's financial outlook. Conversely, Piper Sandler has maintained an Overweight rating, highlighting the exciting potential for SUBLOCADE in addressing opioid addiction.
Securing Additional Orders
Indivior also recently registered an impressive $8.7 million order from the Biomedical Advanced Research and Development Authority (BARDA) for OPVEE®, a medication planned for opioid overdose reversal. This order is poised to enhance emergency response capabilities at a crucial time marked by the ongoing opioid crisis.
Investing and Financial Insights
As Indivior awaits the FDA's decision regarding the label expansion for SUBLOCADE, investors may benefit from understanding the company's recent financial metrics and market performance. As of now, Indivior's market capitalization sits at approximately $1.33 billion, which underscores its significant role in the pharmaceutical sector.
Growth and Projections
The company's revenue showcased an impressive growth rate of 14.47% over the past twelve months, with a recent quarterly growth of 8.33%. This positive trend aligns well with potential market expansion awaiting the FDA's approval for the updates concerning injection sites and the rapid induction process. Analysts anticipate that Indivior's net income will grow this year, with expectations of profitability underpinned by the hopeful labeling changes for SUBLOCADE that could boost sales.
Frequently Asked Questions
What is SUBLOCADE used for?
SUBLOCADE is used for treating moderate to severe opioid use disorder in patients who have been stabilized on a buprenorphine-containing product.
What changes are being proposed for SUBLOCADE's usage?
The proposed updates allow SUBLOCADE to be administered at various sites, including the thigh and upper arm, with a rapid induction protocol.
How does the FDA prioritize its reviews?
The FDA's Priority Review status expedites the review process, aiming for a completion within six months instead of the usual ten months.
What are the common side effects of SUBLOCADE?
Typical side effects include constipation, headache, nausea, tiredness, and injection site pain or itching.
What is the significance of the BARDA order for Indivior?
The $8.7 million order from BARDA for OPVEE® supports emergency response efforts and highlights Indivior's role in combating the opioid crisis.
